VivoSeq
Other

Intra-Abdominal Infection

1

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Intra-abdominal Infection is an early-stage landscape with 1 program across 5 companies. The most active players are Pfizer, Merck & Co., Bayer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalI

Iterum Therapeutics, International Limited

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Recruiting2 · 13%
Terminated1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes
Recruiting·PPeking Union Medical College Hospital·N/A·NCT05052619·297 enrolled
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
Recruiting·—·Phase 3·NCT05148702·1,166 enrolled
A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection
Not yet recruiting·FFujian Medical University Union Hospital·Preclinical·NCT07672496·165 enrolled
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
Completed·Pfizer logoPfizer·Phase 4·NCT00195351·467 enrolled
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT01506271·351 enrolled
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
Completed·Bayer logoBayer·Phase 3·NCT01069900·458 enrolled
Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Completed·Bayer logoBayer·N/A·NCT01096511·1,001 enrolled
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Completed·Pfizer logoPfizer·Phase 4·NCT00230971·473 enrolled
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02739997·100 enrolled
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
Completed·Pfizer logoPfizer·Phase 4·NCT00044928·262 enrolled
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
Completed·Pfizer logoPfizer·Phase 3·NCT04927312·60 enrolled
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT03217136·94 enrolled
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Completed·Pfizer logoPfizer·Phase 4·NCT01721408·470 enrolled
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Completed·IIterum Therapeutics, International Limited·Phase 3·NCT03358576·674 enrolled
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03830333·268 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)